Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Matthew P. Blischak J.D. | President, Secretary & CEO | 558.81k | -- | 1963 |
| Mr. James S. Sigler MBA | Executive Vice President of CMC | -- | -- | 1961 |
Finch Therapeutics Group, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 1
Description
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
November 12, 2024 at 12:00 AM UTC
15-12G: Notice of termination of registration of a class of securities under Section 12(g)
October 31, 2024 at 12:00 AM UTC
25: Notification filed by issuer to voluntarily withdraw a class of securities from listing and registration on a national securities exchange